Lineage Cell Therapeutics, Inc.
LCTX · XNYSCIK 876343fmd_0PZP1J8H497WMV12QPTDCFZXPGManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 3 | 5 | 4 | 2 | 4 | 15 | 9 | 9 | 15 |
| Net interest income | – | – | – | – | 1 | 0 | 1 | – | – | – |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | – |
| Gross profit | 6 | 3 | 5 | 3 | 1 | 3 | 14 | 8 | 9 | – |
| Research and development | 36 | 24 | 21 | 18 | 12 | 34 | 14 | 16 | 12 | 18 |
| Total operating expenses | 65 | 44 | 46 | 42 | 28 | 52 | 36 | 33 | – | – |
| Operating income | (59) | (39) | (42) | (39) | (26) | (49) | (23) | (25) | (21) | (37) |
| Other non-operating income (expense) | 78 | 16 | (5) | 20 | 5 | 6 | (3) | 1 | 3 | (32) |
| Income before taxes | 19 | (23) | (47) | (19) | (22) | (43) | (26) | (23) | (19) | (69) |
| Income tax expense | – | – | 0 | (7) | (1) | – | 1 | (2) | 0 | (5) |
| Net income from continuing operations | – | – | (47) | (12) | (21) | – | (26) | (21) | (19) | (63) |
| Net income | 34 | (20) | (46) | (12) | (21) | (43) | (26) | (21) | (19) | (64) |
| Net income to common shareholders | 34 | (20) | – | – | – | – | – | – | – | – |